Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Kerri Fitzgerald
Articles by Kerri Fitzgerald
Three-Year ZUMA-12 Follow-Up Shows Durable Responses in Patients Treated with Axi-Cel
Kerri Fitzgerald
Aggressive B-Cell Lymphoma
|
December 13, 2023
The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL.
Read More
Study: Bridging Therapy Prior to CAR T-Cell Therapy Is Associated with Prolonged Cytopenia
Kerri Fitzgerald
Aggressive B-Cell Lymphoma
|
December 13, 2023
The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.
Read More
Pirtobrutinib Demonstrates Activity in Patients with MCL Pretreated with a Covalent BTK Inhibitor
Kerri Fitzgerald
Mantle Cell Lymphoma
|
December 13, 2023
Pirtobrutinib is a non-covalent (reversible) BTK inhibitor that inhibits both wild-type and C481-mutant BTK.
Read More
MRD Testing Should Be Done After Four Treatment Cycles in Patients with MCL
Kerri Fitzgerald
Mantle Cell Lymphoma
|
December 15, 2023
Study authors noted that the findings underscore the need for tailored approaches to MRD testing.
Read More
FDA Approves Glofitamab for Relapsed or Refractory DLBCL
Kerri Fitzgerald
Aggressive B-Cell Lymphoma
|
September 30, 2024
The FDA approves the first bispecific antibody for relapsed/refractory DLBCL.
Read More
FDA Approves First Noncovalent BTK Inhibitor Pirtobrutinib for MCL
Kerri Fitzgerald
Mantle Cell Lymphoma
|
February 1, 2023
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Read More
Study Identifies Indicators of Improved Outcomes in Burkitt Lymphoma
Kerri Fitzgerald
Meeting News
|
December 21, 2022
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
Read More
Real-World Study Suggests Cell of Origin in DLBCL May Impact Response to CAR-T Therapy
Kerri Fitzgerald
Meeting News
|
December 21, 2022
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Read More
CALR Mutation in Myelofibrosis Associated with Greater Risk of Anemia
Kerri Fitzgerald
Meeting News
|
February 3, 2023
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Read More
This Chemotherapy-Free Regimen Appears Effective for Ph-Positive ALL
Kerri Fitzgerald
Meeting News
|
February 1, 2023
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
Read More
First All-Oral Triplet Regimen for AML Looks Promising
Kerri Fitzgerald
Acute Myeloid Leukemia
|
February 1, 2023
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Read More
Study Assesses Clearance of Baseline Mutations Following Treatment with Ivosidenib and Azacitidine in AML
Kerri Fitzgerald
Meeting News
|
February 1, 2023
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
Read More
Study Assesses Clinical Trial Recruitment Difficulties in a Lymphoma Cohort
Kerri Fitzgerald
Hodgkin Lymphoma
|
December 10, 2022
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Read More
Phase I Study Demonstrates Benefit of Combination Selinexor, Ruxolitinib for Treatment-Naïve Myelofibrosis
Kerri Fitzgerald
Myelofibrosis
|
April 12, 2023
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Read More
Study Identifies Causes of Increased Risk of Myeloma in Black Americans
Kerri Fitzgerald
Myeloma
|
December 10, 2022
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
Read More
Is Interferon Plus Ruxolitinib Suitable for Newly Diagnosed Polycythemia Vera?
Kerri Fitzgerald
Myeloproliferative Neoplasms
|
May 30, 2023
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Read More
Transfusion-Independence, Survival Improved in Patients with Myelofibrosis Receiving Momelotinib
Kerri Fitzgerald
Myelofibrosis
|
April 12, 2023
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Read More
Longer Follow-Up Shows Sustained Survival Benefit with Venetoclax and Azacitidine for AML
Kerri Fitzgerald
Acute Lymphoblastic Leukemia
|
December 10, 2022
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Read More
Real-World Study Shows Improved Survival with Venetoclax and HMA Combo in IDH-Mutated AML
Kerri Fitzgerald
Acute Myeloid Leukemia
|
December 8, 2022
Venetoclax plus HMAs led to higher response rates than non-venetoclax regimens in patients with newly diagnosed AML.
Read More
Get to Know ... Courtney D. DiNardo, MD, MSCE
Leah Sherwood
Print
|
November 28, 2022
Courtney D. DiNardo, MD, MSCE, talks about mentorship and her research on hereditary cancer predisposition syndromes.
Read More
Load More